Us-Fda Grants Fast Track & Orphan Drug Designations To Rocket Pharma Rp-A601 Gene Therapy For Pkp2 Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals, Inc., A Leading Late-Stage Biotechnology Company Advancing An Integrated And Sustainable Pipeline Of Genetic Therapies For Rare Disorders With High Unmet Need, Announced That The Us Food And Drug Administration (Fda) Has Granted Fast Track And Orphan Drug Designations To Rp-A601, The Company